Literature DB >> 33827606

Antitumor effect of IL-12 gene-modified bone marrow mesenchymal stem cells combined with Fuzheng Yiliu decoction in an in vivo glioma nude mouse model.

Jianjun Wu1,2,3, Shoupin Xie4, Hailong Li1,3, Yanxia Zhang2,3, Jia Yue1,3, Chunlu Yan2,5, Kai Liu2,5, Yongqi Liu2,6, Rui Xu1,2, Guisen Zheng7,8.   

Abstract

BACKGROUND: Glioma is a complex cancer with a high morbidity and high mortality. Bone marrow mesenchymal stem cells (BMSCs) have shown promise as an excellent cell/drug delivery vehicle for gene-targeted therapy; however, maintaining genetic stability and biological activity remains difficult. Furthermore, whether BMSCs support or inhibit tumor growth remains debated. This study investigated whether a traditional Chinese medicine fomular, Fuzheng Yiliu decoction (FYD) had a synergistic antitumor effect with IL-12 gene-modified BMSCs in glioma-bearing nude mice
METHODS: The lentivirus-mediated IL-12 gene was transfected into primarily cultured BMSCs. A total of 72 BALB/c nude mice were used to establish xenograft models with glioma U251 cells and were divided into groups (n = 12) including blank control group, nude mouse model group (model group), lentiviral transfection of BMSC group with no gene loading (BMSC group), IL-12 lentivirus-transfected BMSC group (IL-12 + BMSC group), FYD treatment group (FYD group), and FYD treatment in IL-12 lentivirus-transfected BMSC group (FYD + IL-12 + BMSC group).. After treatment for 14 days, all mice were sacrificed to collect tumor tissue and serum for more detection, such as distribution of BMSCs, cell apoptosis in xenograft tumors, serum IL-12 and INF-γ levels, mouse weight and tumor volume were measured
RESULTS: There were significantly more apoptotic cells in tumor tissue in IL-12 gene transfected group, FYD treatment group and FYD combining with IL-12 gene transfected group than that in the model group (P < 0.05). The FYD + IL-12 + BMSC group showed significantly higher Bax and lower Bcl-2 expression (P < 0.05), and serum IL-12 and INF-γ levels (P < 0.05) were higher than that in all other groups. After the intervention, this group also showed a strong inhibitory effect against tumor growth (P < 0.05)
CONCLUSIONS: This study suggested FYD treatment combined with IL-12 gene-modified BMSCs shows synergistic antitumor effect in glioma-bearing nude mice.

Entities:  

Keywords:  Bone marrow mesenchymal stem cell; Fuzheng Yiliu decoction; Glioma; IL-12

Year:  2021        PMID: 33827606     DOI: 10.1186/s12967-021-02809-2

Source DB:  PubMed          Journal:  J Transl Med        ISSN: 1479-5876            Impact factor:   5.531


  29 in total

Review 1.  Toll-like receptors as a key regulator of mesenchymal stem cell function: An up-to-date review.

Authors:  Solmaz Shirjang; Behzad Mansoori; Saeed Solali; Majid Farshdousti Hagh; Karim Shamsasenjan
Journal:  Cell Immunol       Date:  2016-12-26       Impact factor: 4.868

2.  IFN-γ-primed human bone marrow mesenchymal stem cells induce tumor cell apoptosis in vitro via tumor necrosis factor-related apoptosis-inducing ligand.

Authors:  Jingchun Du; Liwen Zhou; Xiaoyong Chen; Sunxing Yan; Ming Ke; Xiaofang Lu; Zhen Wang; Weihua Yu; Andy Peng Xiang
Journal:  Int J Biochem Cell Biol       Date:  2012-04-24       Impact factor: 5.085

Review 3.  Malignant glioma: lessons from genomics, mouse models, and stem cells.

Authors:  Jian Chen; Renée M McKay; Luis F Parada
Journal:  Cell       Date:  2012-03-30       Impact factor: 41.582

4.  Multilineage potential of adult human mesenchymal stem cells.

Authors:  M F Pittenger; A M Mackay; S C Beck; R K Jaiswal; R Douglas; J D Mosca; M A Moorman; D W Simonetti; S Craig; D R Marshak
Journal:  Science       Date:  1999-04-02       Impact factor: 47.728

Review 5.  Human mesenchymal stem cells and their use in cell-based therapies.

Authors:  Helena Motaln; Cristian Schichor; Tamara T Lah
Journal:  Cancer       Date:  2010-06-01       Impact factor: 6.860

6.  Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype.

Authors:  Raphaëlle Romieu-Mourez; Moïra François; Marie-Noëlle Boivin; Manaf Bouchentouf; David E Spaner; Jacques Galipeau
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

7.  Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFN-gamma, TGF-beta, and cell density.

Authors:  Raphaëlle Romieu-Mourez; Moïra François; Marie-Noëlle Boivin; John Stagg; Jacques Galipeau
Journal:  J Immunol       Date:  2007-08-01       Impact factor: 5.422

8.  Bone marrow mesenchymal stem cells suppress metastatic tumor development in mouse by modulating immune system.

Authors:  Lei Zhang; Xiao San Su; Jun Song Ye; Yi Yin Wang; Zheng Guan; Yan Feng Yin
Journal:  Stem Cell Res Ther       Date:  2015-03-24       Impact factor: 6.832

9.  Gene recombinant bone marrow mesenchymal stem cells as a tumor-targeted suicide gene delivery vehicle in pulmonary metastasis therapy using non-viral transfection.

Authors:  Tian-Yuan Zhang; Bing Huang; Zhong-Yue Yuan; Yu-Lan Hu; Yasuhiko Tabata; Jian-Qing Gao
Journal:  Nanomedicine       Date:  2013-06-12       Impact factor: 5.307

10.  Bone marrow mesenchymal stem cells increase motility of prostate cancer cells via production of stromal cell-derived factor-1α.

Authors:  Barbara Mognetti; Giuseppe La Montagna; Maria Giulia Perrelli; Pasquale Pagliaro; Claudia Penna
Journal:  J Cell Mol Med       Date:  2013-01-10       Impact factor: 5.310

View more
  1 in total

1.  Qu-Du-San-Jie decoction induces growth inhibition and vascular normalization in NF2-associated vestibular schwannoma.

Authors:  Jie Lin; Shi-Wei Li; Jing Zhang; Fu-Hao Chu; Cheng-Ze Li; Zhi-Xu Bie; Han-Lu Tang; Shan Gao; Ping Li; Meng-Ting Liao; Tian-Xi Xin; Fu Zhao; Pi-Nan Liu; Xia Ding
Journal:  Front Pharmacol       Date:  2022-08-19       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.